ADM Tronics Reports Fiscal Year 2025
ADM Tronics (OTCQB:ADMT) reported improved financial results for fiscal year 2025. The company achieved an 8% revenue increase to $3,197,110, driven by growth in engineering services ($232,469) and electronics manufacturing. Gross profit margin improved to 44% from 38% year-over-year.
Operating losses decreased significantly by 89% to $94,024, while net loss improved by 86% to $123,056. The company focused R&D efforts on developing a medical version of Sonotron®, a non-invasive pain treatment technology using pulsed radio frequency, and launched Vet-Sonotron® for veterinary applications.
ADM Tronics (OTCQB:ADMT) ha riportato risultati finanziari migliorati per l'anno fiscale 2025. L'azienda ha registrato un aumento del fatturato dell'8%, raggiungendo 3.197.110 dollari, grazie alla crescita dei servizi di ingegneria (232.469 dollari) e della produzione elettronica. Il margine lordo è salito al 44% rispetto al 38% dell'anno precedente.
Le perdite operative sono diminuite significativamente del 89%, attestandosi a 94.024 dollari, mentre la perdita netta è migliorata dell'86%, arrivando a 123.056 dollari. L'azienda ha concentrato gli sforzi di R&S sullo sviluppo di una versione medica di Sonotron®, una tecnologia non invasiva per il trattamento del dolore basata su radiofrequenza pulsata, e ha lanciato Vet-Sonotron® per applicazioni veterinarie.
ADM Tronics (OTCQB:ADMT) reportó resultados financieros mejorados para el año fiscal 2025. La compañía logró un aumento del 8% en ingresos hasta 3,197,110 dólares, impulsado por el crecimiento en servicios de ingeniería (232,469 dólares) y fabricación electrónica. El margen bruto mejoró al 44% desde el 38% interanual.
Las pérdidas operativas disminuyeron significativamente en un 89% hasta 94,024 dólares, mientras que la pérdida neta mejoró un 86% hasta 123,056 dólares. La empresa centró sus esfuerzos de I+D en desarrollar una versión médica de Sonotron®, una tecnología no invasiva para el tratamiento del dolor que utiliza radiofrecuencia pulsada, y lanzó Vet-Sonotron® para aplicaciones veterinarias.
ADM Tronics (OTCQB:ADMT)는 2025 회계연도에 개선된 재무 실적을 보고했습니다. 회사는 엔지니어링 서비스(232,469달러)와 전자 제조 부문의 성장에 힘입어 매출이 8% 증가하여 3,197,110달러를 달성했습니다. 총 이익률은 전년 대비 38%에서 44%로 향상되었습니다.
영업 손실은 89% 크게 감소하여 94,024달러가 되었고, 순손실도 86% 개선되어 123,056달러에 이르렀습니다. 회사는 펄스 라디오 주파수를 사용하는 비침습적 통증 치료 기술인 Sonotron®의 의료용 버전 개발에 연구개발 노력을 집중했으며, 수의학용 Vet-Sonotron®을 출시했습니다.
ADM Tronics (OTCQB:ADMT) a annoncé des résultats financiers améliorés pour l'exercice 2025. La société a enregistré une augmentation de 8 % du chiffre d'affaires à 3 197 110 dollars, portée par la croissance des services d'ingénierie (232 469 dollars) et de la fabrication électronique. La marge brute est passée de 38 % à 44 % d'une année sur l'autre.
Les pertes d'exploitation ont diminué de manière significative de 89 % pour s'établir à 94 024 dollars, tandis que la perte nette s'est améliorée de 86 % à 123 056 dollars. La société a concentré ses efforts de R&D sur le développement d'une version médicale de Sonotron®, une technologie non invasive de traitement de la douleur utilisant la radiofréquence pulsée, et a lancé Vet-Sonotron® pour des applications vétérinaires.
ADM Tronics (OTCQB:ADMT) meldete verbesserte Finanzergebnisse für das Geschäftsjahr 2025. Das Unternehmen erzielte einen Umsatzanstieg von 8% auf 3.197.110 US-Dollar, angetrieben durch Wachstum im Bereich Ingenieurdienstleistungen (232.469 US-Dollar) und Elektronikfertigung. Die Bruttogewinnmarge verbesserte sich von 38% auf 44% im Jahresvergleich.
Die operativen Verluste verringerten sich deutlich um 89% auf 94.024 US-Dollar, während der Nettoverlust um 86% auf 123.056 US-Dollar verbessert wurde. Das Unternehmen konzentrierte seine F&E-Bemühungen auf die Entwicklung einer medizinischen Version von Sonotron®, einer nicht-invasiven Schmerzbehandlungstechnologie mit gepulster Hochfrequenz, und brachte Vet-Sonotron® für veterinärmedizinische Anwendungen auf den Markt.
- Revenue increased 8% to $3.2M year-over-year
- Operating loss reduced by 89% compared to previous year
- Net loss improved by 86% to $123,056
- Gross profit margin increased to 44% from 38%
- Operating expenses decreased by 23% to $1.49M
- Company still operating at a loss ($94,024 operating loss)
- Chemical segment revenue declined by $14,309
- FDA approval still pending for human medical version of Sonotron
NORTHVALE, NJ / ACCESS Newswire / July 14, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies, products, and proprietary medical devices, announces results for fiscal year ended March 31, 2025.
For the fiscal year ended March 31, 2025, loss from operations was approximately
Revenues for the fiscal year ended March 31, 2025, were
During the fiscal year ended March 31, 2025, ADMT devoted substantial research and development resources to development of the medical version of the Sonotron® for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet. This non-invasive therapy technology utilizes pulsed radio frequency output for the treatment of chronic and acute musculoskeletal pain conditions such as osteoarthritis, tendonitis, and other conditions and diseases. The company plans on pursuing a 510(k) submission to the FDA when the development of the human medical version is completed. The Company commercially introduced the Vet-Sonotron®, a professional veterinary version of this technology for treatment of animals, and is seeking national or regional distributors for sales and marketing to the small animal and equine veterinary markets. See videos:
https://youtu.be/coQUgO7Gssw?si=I9cUOsJ-AnGDyBhO
https://youtu.be/opa-THES9qw?si=LfG8kExhN-EpVJg1
https://youtube.com/shorts/wGVcyaHnd60?si=Y34wwAk565RSnCcS
Complete financial results are available in the Company's Annual Report on Form 10K at www.sec.gov.
Financial Highlights
Fiscal Year Ended | Fiscal Year Ended | |||||||
March 31, 2025 | March 31, 2024 | |||||||
Net revenues | $ | 3,197,110 | $ | 2,965,406 | ||||
Cost of sales | $ | 1,801,450 | $ | 1,848,984 | ||||
Gross Profit | $ | 1,395,660 | $ | 1,116,422 | ||||
Total operating expenses | $ | 1,489,684 | $ | 1,936,318 | ||||
Loss from operations | $ | (94,024 | ) | $ | (819,896 | ) | ||
Total other income (expense) | $ | (27,532 | ) | $ | (57,326 | ) | ||
Loss before provision for taxes | $ | (121,556 | ) | $ | (877,222 | ) | ||
Total benefit (provision) from income taxes | $ | 1,500 | - | |||||
Net loss | $ | (123,056 | ) | $ | (877,222 | ) | ||
Basic and diluted earnings (loss) per common share: | $ | (0.00 | ) | $ | (0.01 | ) | ||
Weighted average shares of common stock outstanding - basic and diluted | 67,588,492 | 67,588,492 | ||||||
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Medical Devices; Medical Device Design, Engineering, Regulatory and Manufacturing Services; and Eco-Friendly, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered and ISO 13485 Certified medical device and manufacturing operations are in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure for research, development and commercialization of diversified technologies.
ADMT welcomes inquiries for its electronics and medical device development and manufacturing services at www.admtronics.com.
To receive ADMT email updates, complete form at https://admtronics.com/investor-relations/
Sonotron® - a registered trademark of ADM Tronics Unlimited, Inc.
Except for historical information contained herein, the matters set forth in this news release are "forward looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's SEC filings, news releases and other communications. The Company assumes no obligation to update information contained in this news release.
Contact:
Andre DiMino
andre@admtronics.com
SOURCE: ADM Tronics Unlimited Inc.
View the original press release on ACCESS Newswire
FAQ
What were ADMT's key financial results for fiscal year 2025?
How much did ADMT's revenue grow in FY 2025?
What is the status of ADMT's Sonotron technology development?
How did ADMT's operating expenses change in FY 2025?
What was ADMT's net loss for fiscal year 2025?
